Evidence map›Paper›PMID 34985883›Full record

ArticleACS chemical biology2022

Small Molecule Calcium Channel Activator Potentiates Adjuvant Activity.

Tetsuya Saito, Nikunj M Shukla, Fumi Sato-Kaneko, Yukiya Sako, Tadashi Hosoya, Shiyin Yao, Fitzgerald S Lao, Karen Messer, Minya Pu, Michael Chan and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Vaccines · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Tetsuya SaitoMoores Cancer Center, University of California San Diego, La Jolla, California 92093-0809, United States.
Nikunj M ShuklaMoores Cancer Center, University of California San Diego, La Jolla, California 92093-0809, United States.ORCID 0000-0002-5150-7827
Fumi Sato-KanekoMoores Cancer Center, University of California San Diego, La Jolla, California 92093-0809, United States.
Yukiya SakoMoores Cancer Center, University of California San Diego, La Jolla, California 92093-0809, United States.
Tadashi HosoyaMoores Cancer Center, University of California San Diego, La Jolla, California 92093-0809, United States.
Shiyin YaoMoores Cancer Center, University of California San Diego, La Jolla, California 92093-0809, United States.
Fitzgerald S LaoMoores Cancer Center, University of California San Diego, La Jolla, California 92093-0809, United States.
Karen MesserHerbert Wertheim School of Public Health and Longevity, University of California San Diego, La Jolla, California 92093-0901, United States.
Minya PuHerbert Wertheim School of Public Health and Longevity, University of California San Diego, La Jolla, California 92093-0901, United States.
Michael ChanMoores Cancer Center, University of California San Diego, La Jolla, California 92093-0809, United States.
Paul J ChuMoores Cancer Center, University of California San Diego, La Jolla, California 92093-0809, United States.
Howard B CottamMoores Cancer Center, University of California San Diego, La Jolla, California 92093-0809, United States.ORCID 0000-0001-7382-0585
Tomoko HayashiMoores Cancer Center, University of California San Diego, La Jolla, California 92093-0809, United States.
Dennis A CarsonMoores Cancer Center, University of California San Diego, La Jolla, California 92093-0809, United States.
Maripat CorrDepartment of Medicine, University of California San Diego, La Jolla, California 92093-0656, United States.ORCID 0000-0002-9011-6845
University of California San Diego · USTokyo Medical and Dental University · JP

Funding

TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES.75N93019C00042 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CARSON, DENNIS · 2019 to 2024
$10.2M
NIAID NIH HHS 75N93019C00042NIAID NIH HHS HHSN272201400051C
6 · The paper itself

Abstract

There remains an unmet need for reliable fully synthetic adjuvants that increase lasting protective immune responses from vaccines. We previously reported a high-throughput screening for small molecules that extended nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) activation after a Toll-like receptor 4 (TLR4) ligand, lipopolysaccharide (LPS), stimulation using a human myeloid reporter cell line. We identified compounds with a conserved aminothiazole scaffold including

Indexed as

Adjuvants, ImmunologicCalcium Channel AgonistsAnimalsBenzamidesCell LineCell ProliferationCytokinesGene Expression RegulationHumansLipopolysaccharidesLymphocytesMiceOvalbuminPiperidinesReceptors, Pattern RecognitionThiazoles2D216Adjuvants, ImmunologicBenzamidesCalcium Channel AgonistsCytokinesLipopolysaccharidesOvalbuminPiperidinesReceptors, Pattern RecognitionThiazoles

Identifiers

PMID34985883
PMCPMC8788586
OpenAlexW4206163169

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.